Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation

International Archives of Allergy and Immunology
H F DvorakD R Senger

Abstract

Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine that is overexpressed in many transplantable animal and autochtonous human cancers, in healing wounds, and in chronic inflammatory disorders such as psoriasis and rheumatoid arthritis. All of these entities are characterized by angiogenesis, altered extracellular matrix, and variable degrees of hypoxia. In addition, two VPF/VEGF receptors, flt-1 and kdr, are overexpressed by endothelial cells that line the microvessels that supply these tumors/inflammatory reactions. On the basis of these and other data, we have proposed a model of angiogenesis in which VPF/VEGF plays a central role: this model is applicable to tumors and also to the angiogenesis that occurs in non-neoplastic processes.

Citations

Oct 3, 1999·Journal of Magnetic Resonance Imaging : JMRI·M V KnoppG van Kaick
Sep 18, 2010·Inflammatory Bowel Diseases·Mirjana JerkicMichelle Letarte
Oct 18, 2002·Journal of Cellular Physiology·Nicole S HarhajDavid A Antonetti
Nov 6, 2002·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Kristine GlundeZaver M Bhujwalla
Feb 17, 2001·The Journal of Pathology·R ClarijsR M de Waal
Dec 4, 1998·Springer Seminars in Immunopathology·N Oppenheimer-Marks, P E Lipsky
May 31, 2012·Archives of Orthopaedic and Trauma Surgery·A M EweidaR E Horch
Feb 4, 2006·Archives of Dermatological Research·Yan ZhangEishin Morita
Jan 9, 2008·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Christopher ChristophiTheodora Fifis
Jan 14, 2011·The Journal of Physiological Sciences : JPS·Atsuo TaharaMasayuki Shibasaki
May 28, 2013·Journal of Dermatological Science·Daniela MarinoMichael Detmar
Nov 14, 1997·The Annals of Thoracic Surgery·D S Winlaw
Oct 19, 2002·Molecular Aspects of Medicine·Masashi NomiShay Soker
Jul 20, 1999·Dermatologic Clinics·J A Reed, A P Albino
May 15, 2002·Trends in Cardiovascular Medicine·Shalini Iyer, K Ravi Acharya
Jan 1, 1997·The International Journal of Biochemistry & Cell Biology·K S Frazier, G R Grotendorst
Mar 6, 2003·BJOG : an International Journal of Obstetrics and Gynaecology·G C WestonP A W Rogers
Dec 20, 1999·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·R G ParryP W Mathieson
Aug 15, 2002·Neuropathology and Applied Neurobiology·Jesús VaqueroSantiago Oya
Feb 1, 2002·Surgery·Yoshihiro KakejiYasunori Emi
Jan 10, 2006·Cancer Biotherapy & Radiopharmaceuticals·Jen-Der Lin, Tzu-Chieh Chao
Dec 2, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Michelle L VarneyRakesh K Singh
Jul 26, 2002·The American Journal of Dermatopathology·Janine ManginiJag Bhawan
Feb 11, 2005·Journal of Pediatric Hematology/oncology·Attias DinaMiselevich Iness
Jun 15, 2013·Mediators of Inflammation·Munkhtugs DavaatserenMi Jeong Sung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.